News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SoLar Pharmaceuticals, Inc. Announces Appointment Of Executive Vice President


10/19/2005 5:10:50 PM

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--April 8, 2004--SoLar Pharmaceuticals, Inc. ("SoLar," "the Company") announced today that Allan S. Kaplan, Ph.D., has joined SoLar as Executive Vice President for Manufacturing and Pharmaceutical Development. In making this commitment Dr. Kaplan is leaving a successful consulting business assisting major pharmaceutical companies in such vital areas as technology transfer, manufacturing site remediation, and product trouble-shooting.

Dr. Kaplan's career in the pharmaceutical industry spans over thirty years. He is a graduate of Temple University's College of Pharmacy, where he received the Rexall Award. Subsequently, he received a Ph.D. in Pharmaceutical Chemistry from the University of Michigan. His pharmaceutical career began in Quality Control at Smith, Kline & French. In 1981, he joined Schering-Plough Corporation (NYSE:SGP), becoming Vice President for Research of its Key Pharmaceuticals, Inc. subsidiary in 1986, and in 1990 he was promoted to Vice President, Pharmaceutical Sciences of Schering-Plough, where he had responsibility for as many as 310 employees with a budget of up to $78 million. Dr. Kaplan also has served Schering-Plough as Dermatology Team Chairman, the inter-disciplinary team that was responsible for new dermatological product development. In 1995, he became Vice President, Research at Dey Laboratories, Inc., a subsidiary of E. Merck AG (currently Merck KGaA), and in 1998, he returned to Florida to found his consulting business.

While at Schering-Plough, Dr. Kaplan played a key role in the development of such blockbusters as the Claritin(R) family of products, Clarinex(R), Intron A(R), and PEG-Intron(R). He has been intimately involved in the development of FDA-approved products in such areas as conventional oral dosage forms, oral controlled-release, oral quick-dissolve Zydis(R) technology, biotechnology, and dermatologicals.

Dr. Kaplan has been elected President both of the Philadelphia Discussion Group (now known as the Philadelphia Forum), and of the Pharmaceutical Development Committee of the Pharmaceutical Manufacturer's Association (currently, PhARMA). He has also been a Director of the Parenteral Drug Association Foundation and has co-authored several peer-reviewed scientific articles.

Lawrence Solomon, M.D., President and Chief Executive Officer of SoLar, stated: "We are truly gratified that Dr. Kaplan has seen fit to give up a thriving consulting practice to join our young company. Dr. Kaplan has had a key role in developing over thirty marketed products. He has substantial expertise in developing products on time and within budget. In addition, Dr. Kaplan has been extensively involved in developing brand extensions including reformulations and combinations; therefore, his background is ideally suited to SoLar's strategy. Dr. Kaplan's full-time commitment to SoLar will allow us to outsource our manufacturing in a high-quality, cost-effective way, and allows us the opportunity to develop innovative pharmaceutical formulations that could substantially enhance our business prospects."

About SoLar

Incorporated in 2001, SoLar Pharmaceuticals, Inc. is a development stage pharmaceutical firm with interests focused on the cardiovascular field.

SoLar is located at 5310 N.W. 33rd Ave., Suite 118, Ft. Lauderdale, FL 33309. Contact Ann Hasen for further corporate information at (954) 535-9150 ext. 100, or at A.Hasen@solarpharm.com.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," " plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the timing and outcome of litigation and future product launches; government regulation generally; competition; manufacturing capacities and output; commercial obstacles to the successful introduction of brand products generally; product liability claims; rising costs and availability of insurance, including product liability insurance; and the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals. SoLar Pharmaceuticals, Inc. disclaims any responsibility to update the statements contained herein.

Contacts

SoLar Pharmaceuticals, Inc., Fort Lauderdale Ann Hasen, 954-535-9150 ext. 100 A.Hasen@solarpharm.com.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES